hBD3(1-23)-hBD4(20-28)-hBD3(33-45), H4

General Information


DRACP ID  DRACP04209

Peptide Name   hBD3(1-23)-hBD4(20-28)-hBD3(33-45), H4

Sequence  GIINTLQKYYCRVRGGRCAVLSCRSQEYRIGRCSTRGRKCCRRKK

Sequence Length  45

UniProt ID  Q8WTQ1 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C218H378N82O59S6

Absent amino acids  DFHMPW

Common amino acids  R

Mass  606926

Pl  11.17

Basic residues  14

Acidic residues  1

Hydrophobic residues  8

Net charge  13

Boman Index  -16482

Hydrophobicity  -84.44

Aliphatic Index  58.44

Half Life 
  Mammalian: 1 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  4845

Absorbance 280nm  110.11

Polar residues  20

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 34025617

Title  A Chimeric Cationic Peptide Composed of Human 尾-Defensin 3 and Human 尾-Defensin 4 Exhibits Improved Antibacterial Activity and Salt Resistance

Doi Not available

Year  2021

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  18491

DRACP is developed by Dr.Zheng's team.